U.S. Pruritus Treatment Market Overview

Pruritus, commonly known as itching, is a common symptom associated with various skin disorders such as eczema, psoriasis, and dermatitis. It can also occur as a side effect of medications or as a symptom of chronic medical conditions including liver disease and kidney failure. Treatment options for pruritus include topical creams, ointments, lotions, oral medications, and phototherapy.

The U.S. pruritus treatment market is witnessing strong growth due to the increasing prevalence of skin diseases, rising geriatric population, and growing awareness regarding chronic itching conditions. Demand for advanced treatment options such as topical corticosteroids, antihistamines, immunosuppressants, and biologics is increasing significantly across the country.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85582

The U.S. pruritus treatment market was valued at US$ 5.1 Bn in 2022 and is projected to reach more than US$ 8.4 Bn by 2031, expanding at a CAGR of 5.6% from 2023 to 2031. Market growth is driven by the increasing incidence of skin disorders, rising elderly population, and growing demand for advanced anti-itch therapies.

Analysis of Key Players in the U.S. Pruritus Treatment Market

The U.S. pruritus treatment market is highly competitive, with leading companies focusing on product launches, mergers & acquisitions, partnerships, and expansion strategies to strengthen their market presence.

Key companies operating in the market include:

• AbbVie, Inc. (Allergan plc)
  · Albireo Pharma, Inc.
  · Astellas Pharma, Inc.
  · Cipla Limited
  · Eli Lilly and Company
  · GSK plc
  · Merck & Co., Inc.
  · Pfizer, Inc.
  · Teva Pharmaceutical Industries Ltd.
  · Viatris, Inc. (Mylan N.V.)
  · Other Prominent Players

These players are investing heavily in innovative biologics, antihistamines, and targeted therapies to improve treatment outcomes and expand their product portfolios.

Key Developments in U.S. Pruritus Treatment Market

• In March 2023, Ipsen acquired Albireo Pharma, Inc. (a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases). The acquisition of Albireo will provide immediate incremental sales and strengthen Ipsen’s rare disease infrastructure. The acquisition is also anticipated to enrich Ipsen’s Rare Disease portfolio, with promising therapeutics for pediatric and adult rare cholestatic liver diseases, innovative pipeline potential, as well as scientific and commercial capabilities.
• In March 2023, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) that is not adequately controlled with the H1 antihistamine treatment, which is the current standard of care. The target action date for the FDA decision is October 22, 2023.
• In July 2021, the U.S. Food & Drug Administration (FDA) approved Bylvay (odevixibat), the first drug approved for the itching treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), which does not require refrigeration and is easily administered as a once-daily capsule or opened and sprinkled onto soft foods.

Analysts’ Viewpoint on the U.S. Pruritus Treatment Market

Industry analysts highlight that the increasing prevalence of chronic skin conditions and growing awareness regarding pruritic disorders are major factors driving market growth. Conditions such as eczema, psoriasis, and dermatitis continue to affect millions of people across the U.S., creating significant demand for effective anti-itch therapies.

The rise in the geriatric population and growing incidence of chronic diseases such as diabetes and kidney disorders are also contributing to market expansion. Older adults are more prone to skin dryness and chronic itching, increasing the need for advanced treatment solutions.

Furthermore, advancements in biologics, immunosuppressants, and targeted drug therapies are expected to create lucrative opportunities for market players. The adoption of telemedicine and OTC medications is also improving accessibility to treatment options across the country.

👉 Discuss Implications for Your Industry or Do you want customize Report, Please Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85582

Key Player Strategies

⚙️ Product Innovation
Development of advanced biologics and targeted anti-pruritic therapies

🌐 Strategic Collaborations
Partnerships, mergers, and acquisitions to expand portfolios

🏥 Expansion of OTC Products
Focus on affordable and easily accessible medications

🔬 R&D Investments
Increasing investment in innovative dermatology treatments

🌍 Digital Healthcare Integration
Growing adoption of telemedicine and online consultations

Challenges

• High cost of advanced biologic therapies
• Side effects associated with prolonged medication use
• Regulatory hurdles for new drug approvals
• Limited awareness regarding chronic pruritic conditions in some populations

Opportunities

⚡ Rising Geriatric Population
Increasing demand for chronic itch management therapies

🏥 Growth in Telemedicine
Improved patient access to dermatology consultations

🌱 Advancements in Biologics
Development of targeted and personalized therapies

💊 Increasing OTC Medication Demand
Growing preference for self-care and affordable treatments

🔬 Ongoing Clinical Research
Expansion of innovative treatment pipelines

Market Segmentation

By Pruritus Type

• Skin Diseases
  • Neuropathic Pruritus
  • Systemic Disease-related Pruritus
  • Psychogenic Pruritus

By Drug Type

• Antihistamines
  • Corticosteroids
  • Immunosuppressants
  • Local Anesthetics
  • Others

By Dosage Form

• Oral
  • Topical
  • Injectable

By Distribution Channel

• Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

• Northeast U.S.
  • Midwest U.S.
  • South U.S.
  • West U.S.

Regional Outlook

The South U.S. and West U.S. regions are witnessing strong growth in the pruritus treatment market due to large patient populations, increasing healthcare access, and rising prevalence of skin diseases.

The Northeast U.S. remains a key market owing to advanced healthcare infrastructure and strong adoption of innovative therapies. Meanwhile, the Midwest U.S. is experiencing steady growth due to rising awareness regarding chronic skin conditions and increasing availability of OTC medications.

Growing healthcare expenditure and expanding dermatology services across all U.S. regions are expected to support continued market expansion through 2031.

Why Invest in the U.S. Pruritus Treatment Market Outlook 2031

✅ Strong market growth driven by increasing prevalence of skin disorders

✅ Rising geriatric population and chronic disease burden

✅ Growing adoption of biologics and advanced therapies

✅ Increasing demand for OTC medications and telemedicine services

✅ Expanding R&D activities and innovative treatment pipelines

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=85582&ltype=S

FAQs

1. What is the projected market size by 2031?

The market is expected to reach more than US$ 8.4 Bn by 2031.

2. What is the CAGR of the market?

The market is projected to grow at a CAGR of 5.6% from 2023 to 2031.

3. What factors are driving market growth?

Rising prevalence of skin diseases, increasing geriatric population, and growing demand for advanced anti-pruritic therapies.

4. Which drug type dominates the market?

Antihistamines dominate due to their effectiveness in treating allergy-related itchiness with fewer side effects.

5. What are key trends in the market?

Growth in biologics, telemedicine adoption, OTC medications, and targeted dermatology therapies.

More Trending Reports by Transparency Market Research –

Foot and Mouth Disease Vaccine Market: https://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Psychotropic Drugs Market: https://www.transparencymarketresearch.com/psychotropic-drugs-market.html

CAR T-cell Therapy Market: https://www.transparencymarketresearch.com/car-t-cell-therapy-market.html

Bacterial Conjunctivitis Drugs Market: https://www.transparencymarketresearch.com/bacterial-conjunctivitis-drugs-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com